Targeting cancer cells with the natural compound obtusaquinone

Journal of the National Cancer Institute

Volumn 105, Issue 9, 2013, Pages 643-653

  Badr, Christian E ^a,b   Van Hoppe, Stephanie ^a   Dumbuya, Hawasatu ^a   Tjon Kon Fat, Lee Ann ^a   Tannous, Bakhos A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; GLUTATHIONE; OBTUSAQUINONE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD CHEMISTRY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CLASSIFICATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CINNAMATES; CYCLOHEXANONES; DNA DAMAGE; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUTATHIONE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877283076     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt037     Document Type: Article

References (25)

1. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol. 2006;24(8):985-995.
2. Szatrowski T P, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51(3):794-798.
3. Toyokuni S, Okamoto K, Yodoi J, et al. Persistent oxidative stress in cancer. FEBS Lett. 1995;358(1):1-3.
4. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579-591.
5. Badr CE, Wurdinger T, Tannous BA. Functional drug screening assay reveals potential glioma therapeutics. Assay Drug Dev Technol. 2011;9(3):281-289.
6. Gregson M, Ollis WD, Redman BT, Sutherland IO, Dietrichs HH, Gottlieb OR. Obtusastyrene and obtustyrene, cinnamylphenols from Dalbergia retusa. Phytochemistry. 1978;17(8):1395-1400.
7. Eslyn WK, Rultman JD, Jurd L. Wood decay inhibition by tropical hardwood extractives and related compounds. Phytopathology. 1981;71(5):521-524.
8. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472-3481.
9. Badr CE, Wurdinger T, Nilsson J, et al. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro Oncol. 2011;13(11):1213- 1224.
10. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401.
11. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radiore-sistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
12. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresist-ance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5(1):67.
13. Vurusaner B, Poli G, Basaga H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med. 2012;52(1):7-18.
14. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001;20(54):7874-7887.
15. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 2002;192(1):1-15.
16. Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011;475(7355): 231-234.
17. Badr CE, Tannous BA. Bioluminescence imaging: progress and applications. Trends Biotechnol. 2011;29(12):624-633.
18. Chaiswing L, Bourdeau-Heller JM, Zhong W, et al. Characterization of redox state of two human prostate carcinoma cell lines with different degrees of aggressiveness. Free Radic Biol Med. 2007;43(2):202-215.
19. Kumar B, Koul S, Khandrika L, et al. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008;68(6):1777-1785.
20. Patel B P, Rawal UM, Dave TK, et al. Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. Integr Cancer Ther. 2007;6(4):365-372.
21. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-310.
22. Peller S. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Semin Cancer Biol. 1998;8(5):379-387.
23. Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008;15(6):959-976.
24. Wu GS. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther. 2004;3(2):156-161.
25. Adams DJ, Dai M, Pellegrino G, et al. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci USA. 2012;109(38):15115-15120.